MABE416
Anti-Cisplatin DNA Adducts Antibody, clone ICR4
clone 1CR4, from rat
Synonyma:
CP9/19, Cisplatin DNA modification
Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Doporučené produkty
biological source
rat
Quality Level
antibody form
purified antibody
antibody product type
primary antibodies
clone
1CR4, monoclonal
species reactivity
human
technique(s)
ELISA: suitable
dot blot: suitable
immunohistochemistry: suitable
isotype
IgG2aκ
shipped in
wet ice
target post-translational modification
unmodified
Související kategorie
General description
Cisplatin adducts are Guanine-Guanine (GG) DNA intrastrand cross links caused by the chemical compound Cisplatin. Cisplatin is used as a chemotherapy agent that contains platinum. The crosslinking of the DNA triggers apoptosis in the effected cell. Cisplatin is particularly effective in certain cancers such as testicular cancer. Unfortunately like most chemotherapy agents Cisplatin has many side effects and cancer cells typically will develop resistance to the drug after a period of time. Clone ICR4 was formerly known as clone CP9/19.
Specificity
This antibody demonstrates specificity for cisplatin modified DNA.
Immunogen
Cisplatin modified native DNA.
Application
Detect Cisplatin adducts using this rat monoclonal antibody, Anti-Cisplatin DNA Adducts Antibody, clone ICR4 validated for use in Dot Blot, ELISA & IHC.
ELISA Analysis: A representative lot from an independent laboratory detected Cisplatin DNA Adducts in ELISA (Tilby, M. J., et al. (1991). Cancer Res. 51(1):123-129.; Kothandapani, A., et al. (2011). J Biol Chem. 286(16):14564-14574.; Welters, M. J., et al. (1999). Ann Oncol. 10(1):97-103.; Strobeck, M. W., et al. (2000). Proc Natl Acad Sci USA. 97(14):7748-7753.; Kothandapani, A., et al. (2012). Exp Cell Res. 18(16):1973-1986.).
Immunohistochemistry Analysis: A representative lot from an independent laboratory detected Cisplatin DNA Adducts in Head and Neck Squamous Cell Carcinoma tissues. (Welters, M. J., et al. (1999). Ann Oncol. 10(1):97-103.).
Immunohistochemistry Analysis: A representative lot from an independent laboratory detected Cisplatin DNA Adducts in Head and Neck Squamous Cell Carcinoma tissues. (Welters, M. J., et al. (1999). Ann Oncol. 10(1):97-103.).
Research Category
Epigenetics & Nuclear Function
Epigenetics & Nuclear Function
Research Sub Category
Chromatin Biology
Chromatin Biology
Quality
Evaluated by Dot Blot in untreated and Cisplatin treated DNA from HeLa cell lysates.
Dot Blot Analysis: A 1:1,000 dilution of this antibody detected Cisplatin DNA Adducts in 1.0 and 0.5 µg of Cisplatin treated DNA from HeLa cell lysates.
Dot Blot Analysis: A 1:1,000 dilution of this antibody detected Cisplatin DNA Adducts in 1.0 and 0.5 µg of Cisplatin treated DNA from HeLa cell lysates.
Physical form
Format: Purified
Protein G Purified
Purified rat monoclonal IgG2aκ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.
Storage and Stability
Stable for 1 year at 2-8°C from date of receipt.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Ještě jste nenalezli správný produkt?
Vyzkoušejte náš produkt Nástroj pro výběr produktů.
Storage Class
12 - Non Combustible Liquids
wgk_germany
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Osvědčení o analýze (COA)
Vyhledejte osvědčení Osvědčení o analýze (COA) zadáním čísla šarže/dávky těchto produktů. Čísla šarže a dávky lze nalézt na štítku produktu za slovy „Lot“ nebo „Batch“.
Již tento produkt vlastníte?
Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.
Zákazníci si také prohlíželi
M Harris et al.
British journal of cancer, 108(4), 859-865 (2013-02-07)
Human papilloma virus (HPV) is implicated in >99% of cervical cancers and ∼40% of head and neck squamous cell carcinoma (HNSCC). We previously targeted E6 oncogene with (188)Rhenium-labelled monoclonal antibody (mAb) C1P5 to HPV16 E6 in cervical cancer and HNSCC.
And-1 Coordinates with the FANCM Complex to Regulate Fanconi Anemia Signaling and Cisplatin Resistance.
Zhang, et al.
Cancer research, 82, 3249-3262 (2023)
Moon Soo Park et al.
Journal of the American Society of Nephrology : JASN, 13(4), 858-865 (2002-03-26)
Cisplatin, a commonly used chemotherapeutic agent, has a major limitation because of its nephrotoxicity. Recent studies have shown that cisplatin causes apoptotic cell death in renal tubule cells, but the underlying molecular mechanisms remain to be elucidated. In this study
Stuart C Williamson et al.
Nature communications, 7, 13322-13322 (2016-11-09)
Small cell lung cancer (SCLC) is characterized by prevalent circulating tumour cells (CTCs), early metastasis and poor prognosis. We show that SCLC patients (37/38) have rare CTC subpopulations co-expressing vascular endothelial-cadherin (VE-cadherin) and cytokeratins consistent with vasculogenic mimicry (VM), a
Yonggen Zou et al.
Oncology letters, 15(1), 1097-1102 (2018-02-06)
As an important chemotherapeutic agent for the treatment of osteosarcoma, the effectiveness of cisplatin is considered to be due to its unique properties, which allow it to penetrate the cell membrane and form various DNA-platinum adducts, resulting in genetic alterations
Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..
Obraťte se na technický servis.